Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
BASEL, Switzerland and CAMBRIDGE, Mass., Nov. 21, 2016 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced two presentations during the 58th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, CA on December 3rd-6th, 2016.
The two presentations will highlight recent work in re-creating the natural condition of hereditary persistence of fetal hemoglobin (HPFH) that is protective in sickle cell disease and beta thalassemia. The presentations will describe the ability to re-create specific HPFH gene variants in the intended target tissue, human primary CD34+ stem cells, and the effect of these gene variants at re-creating the expression of protective fetal hemoglobin. Additional data on progress towards filing an IND or CTA will also be presented.
“We are excited by our progress and we remain focused on our goal of bringing potentially transformative therapies to patients with beta thalassemia and sickle cell disease,” said Dr. Rodger Novak, CEO of CRISPR Therapeutics. "We look forward to discussing data from our recent work at the upcoming ASH conference.”
Details of the presentations are as follows:
| Title: | CRISPR/Cas9 – Mediated Genome Editing of Human CD34+ Cells Upregulate Fetal Hemoglobin to Clinically Relevant Levels in Single Cell-Derived Erythroid Colonies (Abstract #3623) |
| Presenter: | Bibhu Mishra, Ph.D., (Title)), CRISPR Therapeutics |
| Date: | Monday, December 5, 2016, 6:00-8:00PM PT - Hall GH (San Diego Convention Center) |
| Session: | 112. Thalassemia and Globin Gene Regulation: Poster III |
| Title: | Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β-Thalassemia (Abstract #4708) |
| Presenter: | Bill (Sven Ante) Lundberg, M.D., M.B.A, Chief Scientific Officer, CRISPR Therapeutics |
| Date: | Monday, December 5, 2016, 6:00-8:00PM PT - Hall GH (San Diego Convention Center) |
| Session: | 801. Gene Therapy and Transfer: Poster III |
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform.
MEDIA CONTACTS: Jennifer Paganelli W2O Group for CRISPR 347-658-8290 [email protected] INVESTOR CONTACT: Chris Brinzey Westwicke Partners for CRISPR 339-970-2843 [email protected]
